Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.
We describe a patient who became cushingoid as a result of receiving steroid therapy for thrombocytopenia purpura and who then developed spinal epidural lipomatosis 4 months after he started receiving ritonavir as part of his therapy for human immunodeficiency virus infection. We believe that ritonavir may have contributed to the development of epidural lipomatosis and that clinicians should be aware of this possible association.
Ebright
J R
JR
Department of Medicine, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA. JEbright@intmed.wayne.edu
Stellini
M A
MA
Tselis
A C
AC
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004824:Epidural Space; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008068:Lipomatosis / Q000139:chemically induced* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D011696:Purpura, Thrombocytopenic / Q000150:complications / Q000188:drug therapy; D019438:Ritonavir / Q000009:adverse effects*; D013122:Spinal Diseases / Q000139:chemically induced* / Q000473:pathology
D019380:Anti-HIV Agents; D000893:Anti-Inflammatory Agents; D017320:HIV Protease Inhibitors; D003907:Dexamethasone; D019438:Ritonavir